Results 151 to 160 of about 39,038 (256)

One‐year usage patterns of SGLT‐2 inhibitors and GLP‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 972-981, February 2026.
Abstract Aims Real‐world studies of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates these measures to categorize patterns of drug usage.
Louise A. Donnelly, Katyayeni Singh, Rory J. McCrimmon, Ewan R. Pearson   +3 more
wiley   +1 more source

Delayed-Onset Hypoglycemia After Levofloxacin Use in a Diabetic Patient. [PDF]

Case Rep Med
Dwaah H, Tupchong S, Kim J.
europepmc   +1 more source

Ethnic differences in the comparative effectiveness of second‐line type 2 diabetes medications in preventing cardiovascular disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1013-1023, February 2026.
Abstract Aim To investigate ethnic differences in the comparative effectiveness of sulfonylureas (SU), dipeptidyl peptidase‐4 inhibitors (DPP4i) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) on cardiovascular outcomes. Materials and Methods We identified adults with type 2 diabetes in UK electronic health records initiating SU, DPP4i or SGLT2i
Mia Harley, Christopher T. Rentsch, Elizabeth Williamson, Anoop S. V. Shah, Patrick Bidulka, Charlotte Warren‐Gash, Marleen Bokern, Rohini Mathur   +7 more
wiley   +1 more source

Control of Kir channel gating by cytoplasmic domain interface interactions [PDF]

, 2017
Alekseev, Alekseev, Amorós, Antcliff, Bichet, Bushman, Bushman, Clarke, Colin G. Nichols, Drain, Dürr, Enkvetchakul, Enkvetchakul, Enkvetchakul, Eswar, Gloyn, Gribble, Hansen, Hibino, Hilgemann, Huang, Inagaki, Inagaki, Jiang, Koster, Koster, Kumar, Kuo, Kurata, Lederer, Lee, Lee, Lin, Lin, Lin, Linder, Loechner, Lopatin, Lopes, Loussouarn, Loussouarn, Lu, Martin, Nichols, Nichols, Nichols, Nichols, Proks, Proks, Qin, Qin, Qin, Qin, Remedi, Ribalet, Ribalet, Schwalbe, Shimomura, Shizhen Wang, Shyng, Shyng, Shyng, Shyng, Shyng, Shyng, Sievers, Sobolevsky, Sobolevsky, Suh, Sunjoo Lee, Tao, Trapp, Trapp, Whorton, William F. Borschel, Zhang, Zhu, Zubcevic   +77 more
core   +2 more sources

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source

Effectiveness of empagliflozin in reducing hypoglycemic events as compared to sulfonylurea in type 2 diabetes patients during fasting in Ramadan: a single-center study. [PDF]

BMC Endocr Disord
Kiran Z, Fatima N, Baloch AA, Shaikh KUS, Hasan SM, Khan MU.   +5 more
europepmc   +1 more source

New‐onset prediabetes/diabetes worsens overall survival in patients with cancer: A real‐world retrospective cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1247-1257, February 2026.
Abstract Aims Cancer diagnosis may increase the risk of developing prediabetes/diabetes and subsequently worsen survival in cancer patients. However, it is unclear whether this association is influenced by the timing of hyperglycemia onset or the use of antihyperglycemic medications.
Maci Winn, Svenja Pauleck, Stephanie Richardson, Richard Viskochil, Prasoona Karra, Howard Colman, Jennifer A. Doherty, Yizhe Xu, Siwen Hu‐Lieskovan, Michelle Litchman, Mary C. Playdon, Sheetal Hardikar   +11 more
wiley   +1 more source

Targeted analysis of whole exome sequencing in Thai patients with neonatal diabetes. [PDF]

Hum Genet
Plengvidhya N, Tangjarusritaratorn T, Teerawattanapong N, Narkdontri T, Innang S, Songlilitchuwong S, Suthon S, Tangjittipokin W.   +7 more
europepmc   +1 more source

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1304-1314, February 2026.
Abstract Aim PIONEER REAL Saudi Arabia investigated real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes (T2D). Materials and Methods This was a 34‐ to 44‐week multicentre, prospective, open‐label study in adults with T2D, who were treatment‐naive to injectable glucose‐lowering medication ...
Hussein ElBadawi, Nader Albalkhi, Ibrahim Al Kadhim, Ahmed Elsadig, Dimitrios Baltzis, Mohamed Hassan Hatahet, Mahmoud Ismail, Said Khader, Christina Louise Rasmussen, Stine Hedegaard Scheuer, Ahmed Shalaby, Mohammed Almehthel   +11 more
wiley   +1 more source

Genome-Wide Association Study of Hypoglycemia in Adults With Diabetes in the Million Veteran Program. [PDF]

Diabetes
Raghavan S, Litkowski E, Jensen A, Charest B, Wang Z, Hui Q, Chen HC, Rhee MK, Leong A, Meigs JB, Lange L, Lange E, Reaven P, Hung A, Zhou J, Sun YV, Phillips LS, Million Veteran Program*.   +17 more
europepmc   +1 more source